Table 1.
Baseline characteristics of three patients with primitive neuroectodermal tumor.
| Patient characteristics | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Germ cell tumor | |||
| Age at dx, years | 33 | 37 | 24 |
| Stage at dx | III | IA | IA |
| Tumor markers at dx | |||
| BHCG (mIU/mL) | <1 | NL | unk |
| AFP (IU/mL) | 18 | 52.1 | unk |
| LDH (U/L) | 2482 | NL | unk |
| Initial chemotherapy | BEP ×3 | BEP ×4 | BEP ×3, EP ×1 |
| PNET | |||
| Age at dx, years | 33 | 39 | 26 |
| Chemotherapy | VAC/IE ×1, VAC ×4 | VAC/IE ×4 | VAC/IE ×5, IE ×2, Irinotecan ×2 |
| Surgery | Yes | No | No |
| Other therapies | No | CDK inhibitor, Palliative XRT | CDK inhibitor, SCT |
| Clinical outcome | NED | Residual disease | Deceased |
PNET, primitive neuroectodermal tumor; dx, diagnosis; NL, normal; unk, unknown; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; VAC, vincristine, doxorubicin and cyclophosphamide; IE, ifosfamide and etoposide; CDK, cyclin-dependence kinase; XRT, radiation therapy; SCT, stem cell transplant; NED, no evidence of disease.